

Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells

Anna Sole, Sandrine Grossetête, Maxime Heintzé, Loelia Babin, Sakina Zaïdi, Patrick Revy, Benjamin Renouf, Anne de Cian, Carine Giovannangeli, Cécile Pierre-Eugène, et al.

▶ To cite this version:

Anna Sole, Sandrine Grossetête, Maxime Heintzé, Loelia Babin, Sakina Zaïdi, et al.. Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells. Cancer Research, 2021, 81 (19), pp.4994-5006. 10.1158/0008-5472.CAN-20-3837. mnhn-03873854

HAL Id: mnhn-03873854 https://mnhn.hal.science/mnhn-03873854

Submitted on 27 Nov 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. 1 Unraveling Ewing sarcoma tumorigenesis originating from patient-derived

2 Mesenchymal Stem Cells

- 3 Anna Sole¹, Sandrine Grossetête², Maxime Heintzé¹, Loelia Babin¹, Sakina Zaidi², Patrick
- 4 Revy¹, Benjamin Renouf³, Anne De Cian³, Carine Giovannangeli³, Cécile Pierre-Eugène²,
- 5 Isabelle Janoueix-Lerosey², Lucile Couronné^{4,5}, Sophie Kaltenbach^{5,6}, Mark Tomishima^{7,8},
- 6 Maria Jasin⁷, Thomas G. P. Grünewald^{9,10,11,12}, Olivier Delattre², Didier Surdez^{2, 13*†} and Erika
- 7 Brunet^{1*†}
- 8
- 9¹ Institut Imagine, INSERM UMR1163, «Laboratory of Genome Dynamics in the Immune
- System », Équipe Labellisée La Ligue Nationale Contre Le Cancer, University of Paris, Paris,
 France
- ² INSERM U830, Équipe Labellisée LNCC « Genetics and Biology of Pediatric Cancers",
- PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris,
 France
- ³ Museum National d'Histoire Naturelle, Inserm U1154, CNRS UMR 7196, Sorbonne
 Universités, Paris, France
- ⁴ Institut Imagine, INSERM UMR1163, «Laboratory of Onco-Hematology, Laboratory of
- 18 Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical
- 19 Implications», University of Paris, Paris, France
- ⁵ Laboratory of Onco-Hematology, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris (APHP), Paris, France
- ⁶ INSERM U1151, Institut Necker-Enfants Malades, Paris, France
- 7 Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY
 10065, USA
- ⁸ BlueRock Therapeutics, New York, NY 10016, USA
- 26 ⁹ Division of Translational Pediatric Sarcoma Research, German Cancer Research Center
- 27 (DKFZ), Heidelberg, Germany
- 28 ¹⁰ Hopp-Children's Cancer Center (KiTZ), Heidelberg, Germany
- 29 ¹¹ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
- 30 ¹² German Cancer Consortium (DKTK), Partner Site Heidelberg, Heidelberg, Germany
- 31 ¹³ Balgrist University Hospital, University of Zurich, Zurich, Switzerland
- 32 [†] co-corresponding authors
- 33
- 34
- 35 * correspondence to:
- 36 <u>erika.brunet@inserm.fr</u> (E.B)
- 37 <u>didier.surdez@balgrist.ch (D.S)</u>
- 38
- 39 The authors declare no potential conflicts of interest.
- 40
- 41

42 **Funding:**

43 This work was supported by the Institut National du Cancer (PLBIO16-291), by La Ligue 44 Nationale Contre le Cancer (P.R/E.B. and O.D/D.S teams: Équipes Labellisées), the 45 Fondation ARC (L.B.); the AIDA association (M.H.), by grants from the Institut Curie; the 46 INSERM; the Canceropôle Ile-de-France; the projet de Recherche 'Enfants, Adolescents et Cancer': the Agence Nationale de la Recherche (ANR-10-EOPX-03, Institut Curie 47 Génomique d'Excellence (ICGex) and the société française de lutte contre les cancers de 48 49 l'enfant et de l'adolescent. This project also received support from European funding: ERA-TRANSCAN JTC 2014 (TRAN201501238) and TRANSCAN JTC 50 NET 2017 (TRANS201801292). D.S. is supported by the Institut Curie-SIRIC (Site de Recherche 51 52 Intégrée en Cancérologie) program. T.G.P.G. is supported by grants from the Gert and 53 Susanna Mayer foundation, the Barbara and Wilfried Mohr foundation, and the SMARCB1 54 association. We are indebted to the following associations for providing essential support: 55 L'Etoile de Martin, Aida, la Course de l'Espoir, M la vie avec Lisa, ADAM Couleur Jade, 56 Dans les pas du Géant, Courir pour Mathieu, Marabout de Ficelle, Olivier Chape, Les 57 Bagouzamanon, Enfants et Santé, and les Amis de Claire.

58

60 ABSTRACT

61 Ewing sarcoma (EwS) is characterized by pathognomonic translocations fusing most frequently EWSR1 with FLI1. Moreover, around 30% of EwS tumors also display genetic 62 63 alterations in STAG2, TP53, or CDKN2A (SPC). Numerous attempts to develop relevant EwS models from primary human cells have been poorly successful. By engineering the 64 t(11;22)(q24;q12) translocation together with a combination of SPC mutations, we report here 65 66 successful generation of a wide collection of immortalized cells tolerating EWSR1-FLI1 67 expression (EWIma cells) from primary mesenchymal stem cells (MSCs) derived from a EwS patient. Our results revealed that SPC alterations strongly favor EwS oncogenicity. 68 69 Importantly, xenograft experiments with independent EWIma cells induced tumors and 70 metastases in mice which displayed bona fide EwS features. EWIma cells present balanced 71 but also more complex translocation profiles mimicking chromoplexy, which is frequently 72 observed in EwS and other cancers. Collectively, our results demonstrate that bone marrow 73 derived MSCs are a source of origin for EwS and also provide original experimental models 74 to investigate Ewing sarcomagenesis.

75

76 SIGNIFICANCE

We demonstrate that Ewing sarcoma can originate from human bone marrow derived MSCs
and that additional recurrent mutations support the EwS translocation mediated
transformation.

80 INTRODUCTION

81 Ewing sarcoma (EwS) is the second most frequent bone or soft-tissue cancer of 82 children, adolescents, and young adults. It is characterized by a chromosomal translocation 83 between EWSR1 and members of the ETS (E26 transforming-specific) family of transcription 84 factors, most frequently with FLI1 (t(11;22)(q24;q12)) (1). EWSR1-FLI1 exerts a strong oncogenic role but also cytotoxic effects when expressed in various primary cells (2,3). Only 85 86 few additional recurrent genetic alterations are observed in EwS, primarily including 87 inactivating mutations of STAG2 (~15-20%) and TP53 (~5-10%), as well as CDKN2A 88 deletions (~9-22%) (4-6). Co-occurrence of STAG2 and TP53 mutations was reported to be associated with poor outcome (6). However, the pro-oncogenic role of these additional 89 90 mutations in EwS origin and progression remained elusive.

91 Despite numerous efforts to generate murine EwS models, none of them faithfully 92 recapitulated phenotypic, transcriptomic and epigenetic features of EwS (7-11). This may be 93 partially explained by the poor conservation of *cis*-regulatory enhancers containing GGAA-94 microsatellites (mSats) that are uniquely bound by EWSR1-FLI1, and that appear critical for 95 Ewing sarcomagenesis (12). However, several factors such as the exact nature of the cell(s) of 96 origin, the timing and the (co)-occurrence of oncogenic events involved in Ewing 97 sarcomagenesis are still poorly characterized (12). Although EwS histogenesis has been a 98 long-lasting debate, experimental evidence has converged on either a neural crest origin, as 99 neural crest-derived cells appeared to be permissive to EWSR1-FLI1 expression (13), or a 100 mesenchymal origin, as for instance EWSR1-FLI1 inhibition in EwS cells induced features of 101 mesenchymal stem cells (MSCs) (14). However, none of the attempts succeeded to model 102 bona fide EwS tumors in vivo from any types of primary human cells.

103 To better mimic the pathophysiological context of EwS, we and others engineered the 104 *EWSR1-FLI1* translocation using genome editing technologies in human stem cells (15,16).

105 These approaches lead to formation of the specific t(11;22)(q24;q12) translocation, starting 106 from two double-strand breaks (17), one in EWSR1 and the other in FLI1. In contrast to 107 models with ectopic EWSR1-FLI1 expression, the precise generation of the translocation at 108 the endogenous loci enables faithful and 'natural' oncogene regulation, and reproduces 109 heterozygosity at the EWSR1 locus resulting from the translocation of one allele. However, 110 the specific isolation of immortalized/transformed EWSR1-FLI1 translocated clones remained 111 unsuccessful (15,16). To overcome this issue, we reasoned that the genetic background of the 112 starting cells could be of strong relevance. Indeed, the incidence of EwS is much higher in 113 Europeans or European-Americans than in Africans or Afro-Americans (18-20). Genome-114 wide association studies (GWAS) suggest that a specific genetic germline background may be 115 more permissive to EWSR1-ETS translocation and may favor EWSR1-ETS activity (21), as reported for the EGR2 susceptibility locus (22). In addition, we reasoned that additional 116 117 recurrent mutations identified in this cancer may also contribute to Ewing sarcomagenesis. 118 Here, we describe a model generated from primary human MSCs of a European EwS patient 119 by introducing the t(11;22)(q24;q12) translocation and additional alterations in STAG2, TP53 120 and CDKN2A. Strikingly, this model displays molecular and phenotype features of EwS 121 tumor, including expression of EwS-associated markers (including membranous CD99), and 122 efficiently generated EwS tumors and metastases in immunodeficient mice. The bona fide 123 genetically engineered EwS model generated in this study provides novel insights in Ewing 124 sarcomagenesis and highlights the role of additional somatic mutations in this transformation.

125

126 MATERIALS AND METHODS

127 **Primary cell and cell line culture**

128 MSC^{Pat} cells (MSC7-BJ), human primary BMSCs, derived from bone marrow aspirates 129 previously described in (23) and hMPCs described in (24) were cultured in α MEM

130 supplemented with 10% MSC-FBS (12662029; Life Technologies), Glutamine 10mM (Life 131 Technologies) and 2 ng/mL Recombinant Human FGF (233-FB-025; R&D Systems). For 132 these primary cells, written informed consent was obtained according to the Declaration of 133 Helsinki and studies were approved by the ethics committees of the contributing institutions. 134 A673 were cultured in DMEM medium supplemented with 10% FBS (Life Technologies) and cultured at 37 °C in a humidified atmosphere with 5% CO₂ and 20% O₂. MSC^{Pat} and hMPCs 135 136 were cultured in hypoxic-like conditions (3% O₂). Culture cells are tested monthly for 137 mycoplasma contamination using the mycoplasma treatment kit (Myco-1&2 set A8360.0010, VWR). Cells used in the study are fully described in Supplementary Materials. 138

139

140 CRISPR/Cas9 transfections

141 Cells were transfected by 4D Nucleofector Amaxa technology (Lonza) using the cell line 142 nucleofector (solution P1, FF-104) with 1 μ g of plasmid pCAS9-GFP (44719; Addgene) and 143 1 μ g of each plasmid (MLM3636, 43860; Addgene) encoding for the different gRNAs (2 μ g 144 for gRNA^{*EWS*}). For Cas9/gRNA RNP complexes, MSC^{Pat} and hMPCs were transfected 145 directly with the different combination of gRNAs and Cas9-GFP protein (ratio 2:1). gRNA 146 sequences are listed in the Supplementary material.

147

148 **PCR-based translocation detection and frequency**

For detection of translocations from bulk cells, DNA (E.Z.N.A. Tissue DNA Kit, Omega BioTek, GA, USA) was amplified by PCR or Nested PCR, 6 to 8 days post-transfection. Serial
dilutions of DNA enable the assessment of translocation frequency as previously described in
(25). Primer sequences are reported in Supplementary Material.

153

154 Soft-agar colony formation assays

155 A first agar layer was placed in 10 cm plates at 0.8% (w/v) of low melting temperature 156 agarose (50101; Life) in α MEM-10%FBS. Once solidified, a second layer of 0.48% agar 157 containing 4 x 10⁴ cells was added. The plates were maintained at 4 °C for 5 min and 10mL of 158 fresh culture medium was subsequently deposited as a top layer. The plates were incubated in 159 hypoxia conditions and colonies were isolated after 3 to 4 weeks and further analyzed.

160 Counting of colonies was performed using ImageJ/Fiji software and T-test analysis was161 applied.

162

163 Cell proliferation and siRNA assay

164 hMPCs were seeded in 6-well plates (40.000 or 60.000 cells/well) and maintained in hypoxic 165 like or standard conditions for proliferation assay. Cell growth was monitored and analyzed 166 by the IncuCyte Live Cell Analysis system (IncuCyte S3, Essen Bioscience) every 24 hours 167 for 4 to 10 days. For knock-down experiments, 40nM of siRNA against EWSR1-FLI1 (5'-168 GGC AGC AGA ACC CUU CUU A-3') (Eurofins) (or control siRNA (D-001810-01-50; 169 Dharmacon) was transfected using Lipofectamine RNAiMAX Transfection Reagent 170 (ThermoFisher Scientific) following manufacturer's instructions. Cell growth was monitored 171 and analyzed by the IncuCyte system every 4 hours during 3 days. All experiments were 172 independently performed in triplicate, and T-test analysis was applied. SiRNA sequences are 173 reported in Supplementary Material.

174

Fluorescence *In Situ* Hybridization (FISH), multicolor FISH analysis and conventional cytogenetic analysis

Fresh cells with few passages were harvested after 1-6 hours with 10µl/mL of KaryoMAX
colcemid (Gibco) treatment, resuspended in 0.075M KCl at 37 °C for 30 minutes and fixed in
methanol/acetic acid (3:1). Cells were dropped onto glass slides and dried. FISH was

180 performed on the metaphases using EWSR1 and FLI1 probes (LPS007, Cytocell) to detect the 181 t(11;22) chromosomal translocation. Cell images were captured with the Zeiss Spinning Disk 182 Confocal microscopy 63x. Alternatively, for multicolor FISH imaging metaphase spreads 183 were stained with 24XCyte, Multicolor Painting mFISH Probe Kit (MetaSystems), which was 184 prepared following supplier's instructions Metaphases were imaged using a ZEISS 185 AxioImager.Z2 microscope and the Metafer automated capture system (MetaSystems). 186 Karyotyping was performed using Isis software (MetaSystems). For conventional karyotypes, 187 metaphase spreads, R-banded chromosomes were analyzed by standard procedures.

188

189 Flow cytometry

Immunostaining of cells for CD99 marker was performed by incubating cells with FITC
Mouse Anti-Human CD99 (BD Pharmingen, 555688) or FITC Mouse IgG2a, κ Isotype Ctrl
Antibody (Biolegend, 400208) for 30 minutes at 4 °C prior to flow cytometry analysis based
on SS-A/FS-H gating on alive cells (BD FACS Aria II- BD bioscience, and FlowJo software).
Cells labelled with unspecific FITC Mouse IgG2a were used as negative cells for CD99
expression.

196

197 Western blotting

Whole-cell extracts were prepared with protein lysis buffer (50mM Tris-HCl at pH 7.4, 1% Triton X-100, 0.1% SDS, 150mM NaCl, 1mM EDTA, and 1mM DTT), with addition of cocktail protease inhibitor tablets (Complete, Roche). Membranes were stained with FLI1 (ab133485; Abcam) (used to detect the EWSR1-FLI1 translocation), STAG2 (sc81852; Santa Cruz), p53 (sc126; Santa Cruz) or p16 (554079; BD Pharmingen) antibodies. ACTIN (sc1616; Santa Cruz) and VINCULIN (sc73614; Santa Cruz) antibodies were used as loading 204 controls. Membranes were visualized with Odyssey CLx Imaging System (LI-COR205 Biosciences).

206

207 **qRT-PCR**

208 RNA was extracted with the RNeasy Plus Mini Kit (Qiagen) and reverse-transcribed using the 209 High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). gRT-PCRs were 210 performed using PowerSYBR green Mastermix (Applied Biosystems). Oligonucleotides were 211 purchased from MWG Eurofins Genomics (Oligonucleotides and Primers, see Supplementary 212 Materials). Reactions were run on CFX384 Touch Real-Time PCR instrument (Bio-Rad) and 213 analyzed using the CFX Manager Software (Bio-Rad). Relative expression level was assessed 214 with the ddCT method using RPLP0 as a housekeeping gene. Primer sequences are reported 215 in Supplementary Material.

216

217 Telomerase Repeat Amplification Protocol (TRAP)

Fresh cells were resuspended in 100µL of CHAPS Lysis Buffer and TRAP assay was performed following the manufacturer's instructions of TRAPeze Telomerase Detection Kit (S7700, Millipore). PCR products were run on a TBE/acrylamide:bisacrylamide (19:1) gel, stained with SYBR Gold Nucleic Acid Gel Stain (Invitrogen) and visualized with a FLA-3000 Phosphorimager (Fujifilm).

223

224 Telomere Restriction Fragment (TRF)

225 DNA was isolated and digested overnight with HinfI and RsaI enzymes. DNA samples were 226 run in a 0.7% agarose gel overnight and transferred to a membrane. The $[\gamma^{32}P]ATP$ -labeled 227 telomere probe (CCCTAAA)4 was subsequently hybridized by using the Easy Hyb reagent (Roche). Membranes were exposed to Phosphorimager screens and screens were scanned witha FLA-3000 Phosphorimager (Fujifilm).

230

231 SNP array

Infinium Core-24 Chip (Illumina Inc. San Diego, USA) containing more than 300.000 SNPsthat were hybridized with genomic DNA.

234

235 **RNA-seq and bioinformatics analysis**

236 Sequencing was carried out using 2x100 cycles (paired-end reads 100 nucleotides) for all 237 samples on Illumina HiSeq2500 or NovaSeq6000 instruments. Reads were aligned with 238 STAR 2.5.3 (Supplementary Reference 47) to the human genome (GRCh37/hg19 version). 239 We used the count matrix generated by STAR with the human gene annotation v19 of 240 GENCODE as reference. DESEQ2 (Supplementary Reference 48) was used to normalize data 241 and performed differential analysis with the Wald test. The p-value was adjusted using the 242 Benjamini-Hochberg method. We considered a gene expressed if the normalized expression 243 was higher than 10. STAR-Fusion v1.4.0 (Supplementary Reference 49) was applied to predict fusion transcripts. No statistical methods were used to predetermine sample size. 244 245 RNAseq experiments were performed in duplicates or triplicates.

246

247 ChIP-Seq

248 Chromatin Immunoprecipitation (ChIP) experiments were performed following manufacturer 249 instructions using iDeal ChIP-seq kit for transcription factors and for histones (Diagenode) 250 with respectively rabbit polyclonal anti-FLI1 antibody (ab15289, Abcam), rabbit polyclonal 251 anti-H3K4me3 (C15410003, Diagenode) and rabbit polyclonal anti-H3K27ac (ab4729, 252 Abcam). For ChIP sequencing, libraries were generated using TruSeq ChIP library 253 preparation kit (Illumina) and sequenced on Illumina HiSeq 2500 (single end, 100 bp). Reads 254 were aligned to human reference genome (GRCh37/hg19) with bowtie2 2.2.9 (Supplementary 255 Renference 50). Peaks were called with MACS2 2.1.1 (Supplementary Reference 51) with the 256 option narrow for FLI1 ChIP-seq and broad for H3K27ac histone mark. ChIP-seq data were 257 normalized according to their respective input DNA sample. The ChIP-seq signal tracks were 258 generated by macs2 with bdgcmp option (and m FE to compute fold enrichment between the 259 ChIP and the control). Then, we run bedGraphToBigWig to convert the file to a binary format 260 (BigWig). To define enhancers and super-enhancers, we used the ROSE tool (Supplementary 261 Reference 52) with the parameter -t 2500 in order to exclude H3K27ac peaks which overlap 262 the theoretical TSS (<2.5kb) regions. Here defined enhancers were then stitched and therefore 263 some enhancers or super-enhancers can contain active promoters. We annotate them by 264 associating the closest expressed genes. Control-FREEC (29) on input DNA was used to determine Copy Number Variants in EWIma1 (MSC^{Pat} was used as reference). 265

266 Primer sequences are reported in Supplementary Material.

267

268 Mice

269 Animal care and use for this study were performed in accordance with the recommendations of the European Community (2010/63/UE) for the care and use of laboratory animals. 270 271 Experimental procedures were specifically approved by the ethics committee of the Institut Curie CEEA-IC #118 (Authorization APAFIS#11206-2017090816044613-v2 given by 272 273 National Authority) in compliance with the international guidelines. The tumorigenic and 274 metastatic potential of hMPC clones (4-7 mice) or EWIma1, 5 and 7 (2-4 mice per clone) 275 cells was investigated by injecting 1 million cells in an orthotopic intra-osseous model as 276 described previously (Supplementary Reference 53). Seven-week-old NSG (NOD.Cg-277 Prkdcscid IL2rgtm1Wil/SzJ) female mice were purchased from Charles Rivers (France). Mice

were anesthetized by inhalation of a combination isoflurane/air (1.5%, 1 L/min) and followed up for tumor growth. The tumor volume was calculated by using the formula $L \times (12)/2$, where L and I represent respectively the longest and the smallest perpendicular diameter. Tumor samples were fixed for 24 hours in AFA solution and processed for paraffin embedding and sectioning.

283

284 Immunohistochemistry

Xenograft sections (4µm) were cut and stained with hematoxylin and eosin.
Immunohistochemistry was performed using the following antibodies and dilutions: FLI1
1:50 (Abcam, ab15289), STAG2 1:25 (Santa Cruz, sc81852), Ki67 1:500 (Abcam, Ab15580),
cleaved CASP3 1:250 (Cell Signaling, #9661) and CD99 1:1 ready-to-use (Agilent, IS057).

289

290 Data availability

- 291 ChIP-seq and RNA-seq data have been deposited in NCBI's Gene Expression Omnibus under
- accession number: GSE150783.
- Raw data are available at Mendeley. Reserved DOI: doi:10.17632/fx29by5k43.1
- 294 <u>https://data.mendeley.com/datasets/fx29by5k43/draft?a=63bd5c8f-f13b-4100-b9bf-988ddboc9131</u>

295

296

298 **RESULTS**

Generation of stable cell lines expressing EWSR1-FLI1 (EWIma cells) starting from wild type MSCs of an EwS patient

301 Aiming at recapitulating the t(11;22;)(q24;q12) in situ and knowing that the genetic 302 background is a potential factor of incidence in Ewing sarcoma (18), we derived primary normal MSCs of a patient (MSC^{Pat}) (23) who was affected by an EwS of the ulna. The EwS 303 tumor from this patient exhibited four large deletions (chr3q; chr9p comprising CDKN2A; 304 305 chr16q; and chr17p comprising TP53), one gain (chr1q), and an isodisomy (chr5p) at time of 306 diagnosis (Supplementary Fig. 1 and 2A). This tumor also exhibited altered expression of 307 the 3' end of STAG2 (4.90 ratio of average coverage of [Exons 26-30]/[Exons 1-25], compared to 1.62 for MSC^{Pat} cells suggesting the existence of 3' truncated transcripts) 308 309 (Supplementary Fig. 2A), however, without detectable genetic alteration in the coding region of this gene. MSC^{Pat} were derived from a bone marrow aspirate at the time of diagnosis 310 311 and exhibit no copy number alterations (Supplementary Fig. 1). Genomic analyses of these 312 cells confirmed the absence of mutations or alterations in oncogene or tumor suppressor 313 genes. As comparison, we also used mesenchymal stem/precursor cells (hMPCs) derived from 314 human embryonic stem cells which are proficient for multi-lineage differentiation (fat, 315 cartilage, bone, and skeletal muscle)(24). We noticed a growth advantage of hypoxia on cell 316 morphology and proliferation of hMPCs (Supplementary Fig. 2B and C). This is consistent 317 with the observation that the center of solid tumors and the niche of MSCs are mostly hypoxic 318 environments and that hypoxia enhances growth of MSCs (also reported in 25). Based on these results, we cultured MSC^{Pat} and hMPC cells in hypoxic conditions (3% O₂) throughout 319 this study and used the CRISPR-Cas9 technology to engineer the t(11;22)(q24;q12) 320 translocation (26)(Fig. 1A). Upon transfection of Cas9, gRNA^{EWSR1} and gRNA^{FLI1} (EF) 321 coding plasmids in MSC^{Pat}, *EWSR1-FLI1* translocation positive cells were readily detected at 322

323 12 and up to 61 day post-transfection (Supplementary Fig. 2D), although at a lower
324 frequency for the latter time point. However, we could not recover any viable clones in these
325 conditions.

326 We hypothesized that additional somatic mutations found in EwS may facilitate the 327 transformation potential of EWSR1-FLI1 fusion protein. We focused on the three most 328 recurrently mutated genes identified in EwS: STAG2 (S), TP53 (P) and CDKN2A (C), 329 knowing that their expression is also altered in the tumor of origin of this EwS patient 330 (Supplementary Fig. 2A). Using CRISPR-Cas9 and gRNA plasmid transfection, we simultaneously induced the translocation with EF gRNAs with SPC gRNAs in MSC^{Pat} cells 331 332 (Fig. 1A), and could recover numerous clones with SPC mutations. One clone (hereafter 333 termed EWIma1), among hundred isolated clones, displayed morphologic changes with 334 rounder cells, indicative of a gradual acquisition of the classical small-round-cell morphology 335 of EwS cells (2-3 weeks after its isolation, Supplementary Fig. 2E). Three additional 336 independent experiments using the same approach allowed recovering two additional EWIma clones (termed EWIma1* and EWIma1[#]). SNP arrays of EWIma1 cells did not show any of 337 338 the copy number changes found in the patient EwS cells, excluding a hypothetical initial contamination of the MSC^{Pat} with patient tumor cells (Supplementary Fig. 1). In contrast to 339 the original MSC^{Pat}, but similarly to the prototypic A673 EwS cell line, EWIma1 cells stably 340 341 expressed EWSR1-FLI1 oncoprotein (Supplementary Fig. 2F). As expected, these cells did 342 not express STAG2 nor p16 and expressed a truncated form of p53 (Supplementary Fig. 343 2G). Inhibition of EWSR1-FLI1 by RNA interference led to a significant decrease of their 344 proliferation (Fig. 1B) and reverted EWIma1 cells to a more mesenchymal spread-like 345 morphology, as previously described in EwS cell lines (14)(Supplementary Fig. 2H and 2I). 346 Karyotypes and PCR analysis of EWIma1 cells revealed three additional translocations 347 involving chromosomes 9, 11, 13, and 17 (Fig. 1C and 1D, Supplementary Fig. 2J, 2K and

2L and Supplementary Table 1). Most of the breakpoint junctions corresponded to the 348 CRISPR/Cas9 targeted loci or to a predicted off-target site of gRNA^{CDKN2A} located on chr13 349 (in the promoter region of USPL1) (Supplementary Fig. 2K). Only t(9;17) breakpoints, 350 351 which involve the centromere of chr17, could not be amplified by PCR but probably 352 implicates the CDKN2A on chr9 as only one allele of CDKN2A can be amplified. An 353 additional duplication of chr20g, potentially involved in a derivative chromosome 20, was detected in 73% (16/22) of the metaphases (Supplementary Fig. 2L and Supplementary 354 355 Table 1). Similarly to EWIma1, we identified translocations involving chromosomes 9, 11 and 13, 17 in EWIma1^{*} and EWIma1[#] (Supplementary Fig. 2J). Strikingly, these particular 356 chromosomal rearrangements are reminiscent of concomitant intricate genetic events 357 358 previously described as chromoplexy, which is characterized by a sudden burst of complex, 359 loop-like rearrangements (27), found in more than 35% of EwS tumors (28).

To further characterize the EW1ma1 model and to assess whether it faithfully recapitulates EwS properties, we performed ChIP-seq experiments against FLI1 and H3K27ac in MSC^{Pat} and EWIma1 cells. Chromatin patterns for these marks at known EWSR1-FLI1 targets genes in EWIma1 cells strongly resembled those of established A673 EwS cells and noticeably differed from the one of MSC^{Pat} (**Fig. 1E** and **1F**).

365 Importantly, the canonical EWSR1-FLI1 GGAA-mSat and ETS binding motifs (29) 366 were identified as the first and second motifs among all known transcription factor motifs in EWIma1 FLI1 ChIP-seq data (Fig. 1G). Conversely, ETS site was the most prominent 367 identified motif in ChIP-seq peaks in MSC^{Pat} which express FLI1 (Fig. 1G, Supplementary 368 369 Fig. 3A). In EWIma1 cells, 16,338 specific EWSR1-FLI1 peaks were identified (1,741 at 370 GGAA-mSats and 14,597 at ETS binding sites). These specific EWSR1-FLI1 peaks were 371 highly similar to those identified in the A673 cells (Fig. 1H). Strikingly, peaks at GGAAmSat regions were completely absent in MSC^{Pat}. Using H3K27ac ChIP-seq, we further 372

identified 8,685 regions that were specific for EWIma1 compared to MSC^{Pat} (Fig. 1H).
Again, these regions were highly conserved in A673. Furthermore, we performed ROSE
analysis in EWIma1 and MSC^{Pat} cells and identified super-enhancers (SEs) associated to
known EwS-specific genes such as *BCL11B*, *CCND1*, *GLG1*, *NKX2-2*, and *SOX6* (30-32) as
top hits in EWIma1 cells (Supplementary Fig. 3B).

378

379 *De novo* Ewing sarcomagenesis models display heterogeneous morphologies and 380 immortalization patterns, simple and chromoplectic-like phenotypes and are favored by 381 additional mutations.

382 Aiming at obtaining a broad collection of EWIma models by increasing the translocation frequency, we transfected MSC^{Pat} with the ribonucleic protein (RNP)/Cas9 383 complexes (replacing the above plasmid based approach) (33). Very few small colonies grew 384 in agar after transfection with gRNA^{EWSR1} and gRNA^{FLI1} (EF) or together with gRNA^{TP53} 385 (EF+P). In contrast, additional combinations with gRNA^{CDKN2A} (EF+PC) and even more 386 strikingly with gRNA^{STAG2} (EF+SPC) significantly increased the size of these soft agar grown 387 388 colonies (Fig. 2A and 2B). Using EF+SPC conditions, we reached a translocation frequency of 1.6×10^{-3} (Fig. 2C), representing a ~30-fold improvement as compared to plasmid based 389 390 approach (Supplementary Fig. 2D). Remarkably, EF+SPC combination allowed for the 391 identification of 116 PCR positive clones for EWSR1-FLI1 out of a total of 274 isolated 392 clones from these agar plates (Supplementary Fig. 3C). We further kept in culture 30 clones 393 (Supplementary Table 2). Of these, we first randomly selected 13 clones (EWIma2 to 394 EWIma14) for further molecular and cellular characterization, and confirmed expression of 395 EWSR1-FLI1 fusion protein (Fig. 2D) and mutation in SPC genes for all of them (Table 1). 396 Using flow cytometry, we also confirmed higher CD99 expression levels in EWIma clones as compared to MSC^{Pat} mutated in SPC (Supplementary Fig. 3D). Most EWIma clones 397

398 displayed classical EwS cell morphology (Fig. 2E, Supplementary Fig. 3E). Using TRAP 399 assay, most EWIma clones showed strong telomerase activity and grew past 100 days, in 400 agreement with a full immortalized phenotype (Fig. 2F). Interestingly, we observed a more 401 mesenchymal intermediate morphology in some clones (EWIma 11, 12, but also for two 402 additional clones named EWIma 30 and 31) (Fig. 2E, Supplementary Fig. 3E). These intermediate clones appeared to express lower levels of EWSR1-FLI1 transcript 403 404 (Supplementary Table 2) and protein (Fig. 2D), as compared to EWIma models displaying a 405 clear EwS morphology, and also exhibited a lower telomerase activity (Fig. 2F). Karyotype 406 analysis of immortalized EWIma models revealed that 7 out of 13 analyzed clones (EWIma 2 407 to 4 and 6 to 8, 12) displayed a rather simple and stable karyotype with t(11;22)(q24;q12)408 (Fig. 2G and Supplementary Fig. 4A). A few additional somatic alterations could be also 409 detected by simple karyotype, including a loss of 16q (EWIma2), which is also recurrently identified in EwS tumors (Supplementary Fig. 4A). EWIma1, 1^{*}, 1[#], 5, 11 and 14 displayed 410 411 chromoplectic-like translocation patterns (Fig. 1C, 1D, 2H, 2I, Supplementary Fig. 4A). 412 This result is strikingly representative of the recently reported 30-40% incidence of 413 chromoplexy in EwS tumors (28). Whereas the chromoplectic-like pattern of experimental independent EWIma1, EWIma1^{*} and EWIma1[#] clones is almost identical, (Supplementary 414 415 **Fig. 2J**), differences in the translocation patterns were observed in the other complex models. 416 For instance, EWIma5 and EWIma14 showed a chromoplectic-like karyotype with t(11:22) 417 but also the additional translocation t(9;22) (between CDKN2A and EWSR1), addition of 418 chr17p (probably from the TP53 gene DNA break as only one allele can be detected) and loss 419 of STAG2 in all metaphases (Fig. 2H and 2I, Supplementary Fig. 4A and 4B). Altogether, 420 immortalized EWIma1 cells display stable EWSR1-FLI1 expression and faithfully 421 recapitulate EwS cells features.

423 Engineering of t(11;22)(q24;q12) positive cells from multipotent mesenchymal precursor

424 cells

Since MSC^{Pat} cells are extremely limited resources to generate these EwS models, we 425 attempted to reproduce these results using published multipotent mesenchymal precursor cells 426 (hMPCs)(24). An initial translocation frequency above 10^{-3} independently of the presence or 427 428 absence of SPC gRNA could be achieved in these cells (Supplementary Fig. 5A). As reported for MSC^{Pat}, transfection of the unique pair of gRNA^{EWS} and gRNA^{FLII} in hMPCs 429 430 resulted in a progressive loss of the t(11;22)(q24;q12) after two weeks of culture 431 (Supplementary Fig. 5B). However, addition of SPC gRNAs increased the proliferation rate of bulk EF gRNAs transfected hMPCs cells (Supplementary Fig. 5C) and led to longer 432 433 detection (up to 27 days) of *EF* fusion transcript (Supplementary Fig. 5B). Numerous clones 434 grown in soft agar could be isolated from gRNA EF+SPC hMPC transfected cells and 0.9% 435 contained the EwS translocation (3/336 clones). A similar frequency (0.7%, 3/408 isolated 436 clones) of EWSR1-FLI1 positive clones was obtained if only additional gRNAs targeting 437 TP53 and CDKN2A (but not STAG2) were used. Small colonies were obtained in soft agar when gRNA^{EWS} and gRNA^{FLII} were transfected alone, but they could ultimately not be 438 439 recovered after isolation.

440 We further analyzed EWSR1-FLI1 translocated clones, with and without STAG2 441 mutations (Supplementary Fig. 5D to 5K). As in EwS cells, we could detect the EWSR1-FLI1 fusion transcript in all clones, with STAG2 WT clone 1 exhibiting a very low level of 442 443 transcript (Supplementary Fig. 5F and 5G). Expression of EWSR1-FLI1 was detected in 3 444 clones for which we collected sufficient protein extract, confirming the low level of fusion 445 protein in STAG2 WT clone 1 (Supplementary Fig. 5H). TP53 was mutated in these clones 446 which expressed a truncated p53 protein (Supplementary Fig. 5E and 5I). CDKN2A 447 mutations were also present in all four clones (Supplementary Fig. 5E). While no p16

expression was detected for the STAG2 knockout (KO) clones, the STAG2 WT clone 1 448 449 showed p16 expression (related to the induced mutation that leads to a late stop codon) 450 (Supplementary Fig. 5E and 5I). All clones expressed the EwS-specific cell surface marker 451 CD99 (Supplementary Fig. 5J). However, and in contrast to EWIma clones obtained from MSC^{Pat}, none of these EWSR1-FLI1 translocated clones was fully immortalized in vitro and 452 453 they all stopped growing after 2–3 months in culture (after agar selection). During that time, 454 we observed a progressive telomere shortening associated with a weak telomerase activity, 455 factors known to be deleterious for long-term culture (Supplementary Fig. 5K).

456

Transcriptomic analysis of t(11;22)(q24;q12) engineered mesenchymal precursor models revealed a palette of EWSR1-FLI1 activation signature in these cells

459 To further characterize the different models generated so far, we performed transcriptomic analyses in hMPCs, MSC^{Pat} cells, and the derived models containing either the 460 461 EWSR1-FLI1 translocation and/or SPC mutations. These results were compared to 462 transcriptomic profiles of 31 established EwS cell lines. Principal component analysis (PCA) 463 revealed a striking weight of the first component (PC1) as compared to the other ones (Fig. **3A**). PC1 was clearly associated with EWSR1-FLI1 expression (Fig. 3B). Importantly, most 464 465 EWIma1 cells clustered close to a collection of EwS cells but far apart from their parental MSC^{Pat}. Conversely, MSC^{Pat} with or without SPC mutations co-localized on PC1 axis and 466 467 were moderately segregated by PC2 and PC3. Short-term silencing of EWSR1-FLI1 in 468 EWIma1 cells reverted their PC1 component (Fig. 2B and Supplementary Fig. 2H, 2I and 6A). Interestingly, EWIma 11, 12, 30 and 31 models (termed hereafter EWIma^{low} models), 469 470 which displayed a more mesenchymal intermediate morphology (Fig. 2E and 471 Supplementary Fig. 3E) and a moderate telomerase activity (Fig. 2F) were clearly segregated from the other EWIma models (EWIma^{high}, defined hereafter as all EWIma models 472

except EWIma^{low}) on the PC1 axis (Fig. 3B). Similarly, using an unsupervised hierarchical 473 clustering analysis (HCA), all EWImahigh in vitro clones emerged distinctly of the original 474 MSC^{Pat}, hMPCs and EWIma^{low}, from a slightly distant branch compared to EwS patient cells 475 (Fig. 3C). In contrast, engineered clones obtained from hMPCs cells clustered in between 476 477 EwS cell lines and their parental cells (Fig. 3C). Quite remarkably, EWSR1-FLI1 expression appeared as the key factor driving the segregation of mesenchymal cells from EwS 478 populations in both PCA and HCA. MSC^{Pat} carrying SPC alterations or hMPC-derived 479 480 models displaying lower EWSR1-FLI1 levels (in particular clones 1 and 2 from hMPCs WT STAG2) (Fig. 3B and 3C), clustered close to WT MSC^{Pat} or hMPCs (Fig. 3C). To measure 481 482 PC1 activity and evaluate the transition state of a broader collection of EWIma models 483 without having to perform RNA-seq for each clone, we wondered if a small panel of known 484 EWSR1-FLI1 transcriptional activated (EGR2, NKX2-2, PRKCB) (21,26,27) and repressed 485 (TNC, DKK1, IGFBP3) target genes could be used as a surrogate marker using an RT-QPCR approach. For this, we defined an "EWINGness" score as the sum of log2FC (EGR2 + NKX2-486 2 + PRKCB) - (TNC + DKK1 + IGFBP3). Quite remarkably, a strong correlation (R²=0.93) 487 between PC1 and EWINGness scores was observed in MSC^{Pat} and EWIma models 488 489 (Supplementary Fig. 6B). A similar observation was made when all data were considered $(R^2=0.85)$ and not surprisingly, this correlation was poor among EwS cell lines $(R^2=0.08)$ 490 491 (Supplementary Fig. 6B). Using this approach, we were able to evaluate the "EWINGness" 492 of 30 EWIma clones (Supplementary Table 2) emphasizing a broad palette of EWSR1-FLI1 493 activation signature in these models (Supplementary Fig. 6C). Indeed, clones that were negative for the EWSR1-FLI1 translocation but mutated for SPC typically displayed a 494 EWINGness score below 25. Independently of an analysis on their morphological aspect, 495 EWIma^{low} model had an intermediate EWINGness score which was comparable to EWIma1 496 cells silenced for EWSR1-FLI1. Similarly, hMPC-derived models, which were not fully 497

transformed, clearly scored in the intermediate 25-50 window. All other EWIma models 498 499 presenting an EWSR1-FLI1 translocation had a score > 50, which was also observed in a 500 panel of 22 EwS cell lines (Supplementary Fig. 6C). We further explored the transcriptomic signature between MSC^{Pat} and EWIma models using gene-set enrichment analysis (GSEA). 501 502 Heatmap of the top50 features for each phenotype highlighted again the intermediate signature of EWIma^{low} models (Supplementary Fig. 6D). These last were removed from 503 further GSEA to identify gene set signatures correlated with MSC^{Pat} or EWIma^{high} models. 504 505 Quite remarkably, published EWSR1-FLI1 activation signatures ranked among the top50 506 EWIma correlated signatures (among 18580 investigated signatures) (Supplementary Table 507 3). Similarly, four E2F family member signatures were also identified in this top50 (Fig. 3D, 508 Supplementary Table 3). Among those and of particular interest, E2F3 was previously 509 shown to co-localize with EWSR1-FLI1 and to participate in the deregulation of cell cycle 510 control of EwS (34). Conversely, signatures associated with a mesenchymal state were strongly enriched in MSC^{Pat} GSEA analysis (Fig. 3D, Supplementary Table 3). 511

512

513 EWIma cells display tumorigenic and metastatic properties in mice

514 Ultimately, to evaluate the ability of the above described models to give rise to tumors 515 in vivo, we performed orthotopic intra-femoral xenograft experiments. When injecting four 516 hMPC derived models (STAG2 KO clone 1, n=4; STAG2 KO clone 2, n=4; STAG2 WT 517 clone1 hMPC, n=4; STAG2 WT clone2 1, n=3), no tumors were detected in any of these mice 518 after 5.5 months. Remarkably, when injecting two chromoplectic-like EWIma models 519 (EWIma1, n=4 and EWIma5, n=2) and one simple rearranged model (EWIma7, n=4), all 520 mice developed tumors that reached ethical endpoint criteria within 44-60 days (EWIma1), 521 84-90 days (EWIma7) and 90 days (EWIma5) post injection. These tumors were positive for 522 t(11;22;)(q24;q12) and expressed EWSR1-FLI1 (Fig. 4A). Necropsy revealed distant 523 metastases to the lungs and liver with all 3 models. Histological analysis evidenced a typical 524 EwS small-round-cell morphology at primary and metastatic sites (Fig. 4B, Supplementary 525 Fig. 7 A and 7B). Immunohistochemistry (IHC) experiments confirmed a strong and 526 homogeneous CD99 membrane staining, a nuclear FLI1 pattern and absence of nuclear 527 STAG2 expression (Fig. 4B, Supplementary Fig. 7A and 7B). These tumors were highly proliferative and displayed a non-apoptotic pattern as revealed respectively by Ki67 and 528 529 cleaved caspase 3 staining (Fig. 4B, Supplementary Fig. 7A and 7B). Finally, we profiled 530 these EWIma tumors using RNA-seq. Notably, using unsupervised hierarchical clustering 531 analysis (HCA), transformed EWIma1, 5 and 7 tumors clustered together with EwS cells, whereas their in vitro respective models emerged from a more distant branch (Fig. 3C). 532 533 Similarly, these tumors were clearly more left shifted on PC1 axis as compared to their 534 respective *in vitro* counterparts (Fig. 3B). All together, these EWIma models likely represent 535 a novel and large panel of *de novo* generated EwS cellular models with immortalized and 536 transforming properties.

538 **DISCUSSION**

In the present work, we successfully and efficiently generated EWSR1-FLI1 539 540 transformed cells starting from "normal" non-cancerous MSCs of a EwS patient. These 541 models (EWIma) faithfully recapitulated bona fide EwS characteristics, including cell 542 morphology, transcriptomic, epigenetic, metastatic and plasticity aspects that have been previously reported in EwS cells lines and tumors (12). In addition, we defined here a 543 544 EWINGness score as a simple surrogate marker to evaluate transformation potential of 545 mesenchymal stem cells towards Ewing sarcoma. Our results further support that these MSC^{Pat} are permissive to EWSR1-FLI1 expression under its EWSR1 endogenous promoter 546 547 and ultimately leads to their transformation in vivo. This demonstrates that Ewing sarcoma 548 can originate from human bone marrow-derived MSC as previously anticipated but never 549 demonstrated so far (8, 9, 11, 14). Whereas this cell is the only permissive one remains to be 550 formally elucidated. For instance, repeating our experimental approach in neural-crest-derived 551 or other stem/progenitor populations would be complementary to define if various cells of 552 origin in EwS exist (13,35,36). The EwS tumor generated in this study combines endogenous 553 EWSR1-FLI1 translocation together with most recurrent mutations found in EwS. How 554 STAG2, TP53, and CDKN2A alterations specifically contribute to transformation in our model 555 remains to be clarified in future studies. However, even if the SPC mutations appear to confer 556 a growth advantage to mesenchymal stem cells (Supplementary Fig. 5C), they do not appear to confer a "primed" Ewing transcriptomic signature (MSC^{Pat} vs MSC^{Pat}_SPC), which is 557 clearly mediated by the EWSR1-FLI1 transcription factor in our MSC^{Pat} or hMPC derived 558 559 models (Fig. 3B and 3C). STAG2 and TP53 mutations can co-occur in EwS at diagnosis and 560 appear to define an aggressive subtype (6). We also recently demonstrated that STAG2 loss-561 of-function (LOF) mutations reduced the cis-mediated activity of EWSR1-FLI1 (37). In that respect, we can speculate that STAG2 LOF in EWIma models may attenuate the known 562

563 EWSR1-FLI1 toxicity and therefore favors the emergence of these clones. We also showed 564 that STAG2 LOF increased migratory properties of EwS cells, including in EWIma1 cells 565 (37), which was also previously reported at the clinical level to be associated with metastasis 566 (5) and poor outcome (4). In possible support of this notion, orthotopically engrafted 567 EWIma1, 5 and 7 cells also grew at distant sites such as in the lungs and liver. In addition, the 568 original EwS tumor cells of this patient displayed two chromosomal deletions containing 569 CDKN2A and TP53 at the time of the diagnosis, and gene expression data showed a transcript 570 alteration of STAG2 (Supplementary Fig. 2A). These findings raise the possibility that the 571 simultaneous alteration of p16, p53 and STAG2 expression had a direct "boosting" effect on 572 Ewing sarcomagenesis in this particular patient. Whereas individual or combined SPC 573 mutations in this particular patient tumor or more generally in EwS are concomitant to the 574 translocation in EwS tumors or appear as secondary events remains to be elucidated, and both 575 scenarios may occur. Since SPC mutations are absent from many EwS tumors at the time of 576 diagnosis, it is likely that other combinations of more private mutations together with the 577 pathognomic translocation may also allow to successfully transform MSC into faithful EwS 578 models. Indeed, on average, ten coding variants per tumor were detected in EwS tumors at the 579 time of diagnosis (6) and 120 unique genes were involved in chromoplectic breakpoints in 580 Ewing sarcoma (28). Finally, the time scale and the *in vitro* aspects of our approach may also explain why we only transformed few MSC^{Pat} with the EF+SPC cocktail as several years 581 582 and/or microenvironmental factors may be necessary to fully transform a cell of origin. For 583 instance, using clock-like mutation signatures in primary and relapse EwS tumors, it was 584 estimated that the cell that would give rise to the relapse existed years before diagnosis (28). 585 The over-proportional weight of the first PCA component and the GSEA signatures (Fig. 3A 586 and **3D**) highlighted that the EWSR1-FLI1 transcriptional signature is the predominant 587 feature in our model. Notably, the EWSR1-FLI1 binding pattern at both GGAA-mSats and

588 canonical ETS-like binding sites in EWIma1 were strikingly overlapping with that of the 589 established A673 EwS cell line but highly divergent from the FLI1 binding pattern observed in MSC^{Pat} (Fig. 1G and 1H). Acquisition of well-known SEs, reminiscent of a specific EwS 590 identity, clearly demonstrates that EWIma1 cells also display bona fide (neo)-enhancer 591 592 properties for EWSR1-FLI1 (Fig. 1H). Hierarchical clustering showed that EWIma tumors 593 cluster within a large panel of EwS cell lines. Yet, PC2 which mostly discriminated hMPC and MSC^{Pat} derived models, also slightly segregated EWIma1 from EwS cell lines (Fig. 3B). 594 595 Interestingly, all EWIma tumors display additional 'EWINGness' (similar PC1 values to EwS 596 cell lines) as compared to their respective EWIma in vitro models (Fig. 3B and 3C). 597 Exogenous signaling from the microenvironment may account for this difference but remains 598 to be determined.

599 In this study, we suggested the existence of a 'permissive milieu' that could alleviate 600 the potential toxicity of EWSR1-FLI1 expression while favoring its appropriate 601 regulation. We recently demonstrated using GWAS that at least 6 loci were significantly 602 associated with Ewing sarcoma (21). Future experiments, using MSCs with different 603 genotypes at susceptibility loci will enable to more precisely decipher the key genetic 604 elements that are required for EWSR1-FLI1-induced transformation. Besides, recent single 605 cell RNA-seq study of EwS patient-derived xenograft (PDX) tumors highlighted a window in 606 which EwS cells can proliferate (23). Low levels of EWSR1-FLI1 were associated with 607 mesenchymal and apoptotic phenotypes (14, 38), while EwS cells displaying very high 608 EWSR1-FLI1 activity led to absence of proliferation and HIF1a pathway activation (23). In 609 that respect, the collection of EWSR1-FLI1 positive clones generated in this study display a 610 broad and heterogeneous range of EWINGness scores, possibly recapitulating various levels of EWSR1-FLI1 transcriptional activity. However, although all EWIma models generated 611 from MSC^{Pat} carried EWSR1-FLI1 translocation and SPC mutations, not all displayed fully 612

613 immortalized patterns indicating that additional factors (e.g. stemness, cell cycle, oxphos
614 status...) may contribute to the transformation of the EwS cell of origin. Additional
615 investigation with these valuable models will be necessary to answer these key questions.

Here, we also attempted but did not succeed to engineer a transformed EwS model with hMPC cells. Whereas hMPC cells display a *bona fide* multipotent differentiation potential (24), we anticipated that MSC derived from healthy adolescent bone marrow (match of MSC^{Pat} conditions) would have been a better control. However, we could not collect such controls due to the very limited occurrence of such pediatric samples.

621 Besides modelling Ewing sarcomagenesis, we genetically engineered cells with 622 different karyotypes, including some that are reminiscent of chromoplexy (EWIma 1, 5 and 623 14), which has been described in \sim 35% of EwS tumors. Chromoplexy comprises multiple 624 chromosomal translocations that reshuffles chromosomes in a new and scrambled 625 configuration instead of creating simple reciprocal translocations. Recently, chromoplexy has 626 been described in 17.8% of 2,648 whole-cancer genomes from 38 tumor types (39,40) and 627 plausibly as the source of their oncogenic transformation. However, if the exact mechanism of 628 chromoplexy remains to be fully elucidated, modelling this event, as made possible with our 629 gRNA cocktail approach, is of major interest for cancer research. Indeed, in our EWIma 630 models, most chromoplectic-like rearrangements were proved to be initiated at gRNA target 631 sites (and off-target sites for gRNA^{CDKN2A}), indicating that they originated from a single burst in MSC^{Pat} at the time of *EWSR1-FLI1* translocation formation as suggested by genomic data 632 633 on EwS tumors (28). In addition, genomic regions implicated in chromoplexy are often found in early replicating regions, rich in expressed genes (27, 28, 41). Remarkably, all loci 634 635 implicated in chromoplectic-like events in EWIma1 cells (including the intergenic off-target site of gRNA^{CDKN2A}) were located within early replicating domains of the human MSC 636 genome (Supplementary Fig. 7C)(42). In that respect, our approach may represent an 637

attractive model to investigate how 'normal' cells adapt to such a catastrophic burst of
rearrangements. In addition to chromoplexy, chromosomal alterations that have been
observed in EwS are also present in some of our EWIma models. For instance, a duplication
of chr20q is observed in EWIma1. In EwS, trisomy or focal amplifications of chr20 have been
described in up to 15% of these tumors (43, 44). Similarly, deletion of chr16q observed in
EwS tumors (43,44) is particularly obvious in EWIma2 cells (Supplementary Fig. 4A).

644 Recent studies allowed to reconstruct clonal and temporal evolution of tumors using 645 mutational signatures, multiple spatio-temporal tumor sampling and/or single cell sequencing 646 approaches. These top-down approaches allow to speculate about the timing of genetic lesions 647 in the cell of origin without, however, achieving this original stage (40, 45). Our bottom-up 648 strategy is very complementary to these approaches that were also used in EwS to speculate 649 about the timing of the translocation and of the additional alterations. In addition, since EwS 650 genetic susceptibility loci have been identified (21), it would be interesting to expand this 651 collection when starting form additional untransformed cell of origin collections (possibly 652 derived from EwS and non-EwS patients) which may ultimately allow to determine how 653 eQTL related genes affect Ewing sarcomagenesis. Combining top-down and bottom-up 654 strategies may ultimately allow to answer these complex questions, especially in sarcoma 655 where many new entities are presumed to be driven by candidate gene fusion oncogenes (46).

In conclusion, this work demonstrates that EwS can originate from bone marrow derived mesenchymal stem cells. It further provides evidence of the necessity to reach a minimal level of EWSR1-FLI1-mediated transcriptional activity, within a defined genomic susceptibility context, to achieve full immortalization and transformation of this cell of origin. All together, we successfully bypassed here the challenge of modeling EwS *ab initio*. Our model mimics a rather aggressive form of EwS with *SPC* mutations displaying single balanced EWSR1-FL1 translocation but also chromoplectic-like events and transforming 663 properties in mice. Our successful approach to generate *bona fide* EwS cells opens broad 664 avenues to gain important insights into Ewing sarcomagenesis but also into mechanisms 665 related to chromoplexy. More generally, this transposable approach shall allow to investigate 666 sarcomagenesis in the highly heterogeneous family of sarcoma tumors.

667

668 Author contributions:

669 A.S., M.H., L.B., S.Z., P.R., B.R., C.P.E., T.G.P.G. and D.S. carried out experiments. S.G. 670 performed the bioinformatics analyses. S.G. analyzed processed sequencing data. A.D.C. and C.G. produced and provided key reagents. L.C. and S.K. analyzed karyotypes of EWIma 671 672 clones. G.P and F.T. provided patient sequencing data. M.T., I.J.L and M.J. provided cells 673 and valuable expertise. O.D., D.S. and E.B. originally conceived the project, designed the 674 experiments and supervised the work. A.S., D.S. and E.B wrote the paper with the help of 675 O.D., M.J., and T.G.P.G. who provided valuable feedback, and all authors reviewed and 676 agreed on the final manuscript.

677

678 Acknowledgements

679 We thank the iPS (Nathalie Lefort), Imagine cytometry (Olivier Pellé), and microscopy 680 (Meriem Garfa-Traore) platforms for help with SNP karyotyping, cell analysis and image 681 analysis, Lina El Kassar (CECS/I-STEM), Dr. Chloé Lescale and Dr. Ludovic Deriano 682 (Institut Pasteur) for help with the multicolor FISH analysis and Dr. Marion Piganeau for 683 technical support and helpful discussions. We thank Rosalie Borry and each member of the 684 'Genome Dynamics in the Immune System' lab for scientific discussions and technical 685 support. We thank E. Lapouble, G. Pierron, C. Thirant, R. Leclerc, V. Raynal, S. Baulande, P. 686 Legoix, C. Kamoun, M-M. Aynaud and E. Barillot and all members of the Genetics and 687 Biology of Pediatric Cancers laboratory for helpful discussions and/or technical or

- 688 bioinformatics assistance. We thank H. Kovar for providing Ewing sarcoma cell lines and
- 689 COG Childhood Cancer Repository for the CHLA cell line.
- 690

691 **References**

- Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, *et al.* Gene fusion
 with an ETS DNA-binding domain caused by chromosome translocation in human
 tumours. Nature **1992**;359:162-5
- 695 2. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI
 696 induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell
 697 2002;1:393-401
- Sohn EJ, Li H, Reidy K, Beers LF, Christensen BL, Lee SB. EWS/FLI1 oncogene
 activates caspase 3 transcription and triggers apoptosis in vivo. Cancer Res
 2010;70:1154-63
- 4. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, *et al.* The genomic
 landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.
 PLoS Genet 2014;10:e1004475
- 704 5. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, *et al.*705 The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 2014;4:1326-41
- 706 6. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, *et al.* Genomic
 707 landscape of Ewing sarcoma defines an aggressive subtype with co-association of
 708 STAG2 and TP53 mutations. Cancer Discov 2014;4:1342-53
- 709 7. Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, *et al.* Combined
 710 experience of six independent laboratories attempting to create an Ewing sarcoma
 711 mouse model. Oncotarget 2017;8:34141-63
- Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, *et al.*Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal
 progenitor cells. Cancer Res 2005;65:11459-68
- 715 9. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL, Jr. Expression of the
 716 EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1717 dependent, ewing sarcoma-like tumors. Cancer Res 2005;65:8698-705
- El Beaino M, Liu J, Wasylishen AR, Pourebrahim R, Migut A, Bessellieu BJ, *et al.*Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem
 cells. BMC Cancer 2020;20:3
- Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, *et al.* EWS-FLI-1
 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell
 reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010;24:916-32
- 724 12. Grünewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Alava E, Kovar H, *et al.* Ewing sarcoma. Nat Rev Dis Primers **2018**;4:5
- von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, Cooper A, *et al.*Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One **2011**;6:e19305
- Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal
 stem cell features of Ewing tumors. Cancer Cell 2007;11:421-9
- Piganeau M, Ghezraoui H, De Cian A, Guittat L, Tomishima M, Perrouault L, *et al.*Cancer translocations in human cells induced by zinc finger and TALE nucleases.
 Genome research 2013;23:1182-93

- Torres-Ruiz R, Martinez-Lage M, Martin MC, Garcia A, Bueno C, Castano J, *et al.*Efficient Recreation of t(11;22) EWSR1-FLI1(+) in Human Stem Cells Using
 CRISPR/Cas9. Stem Cell Reports 2017;8:1408-20
- 737 17. Brunet E, Simsek D, Tomishima M, DeKelver R, Choi VM, Gregory P, et al.
 738 Chromosomal translocations induced at specified loci in human stem cells. Proc Natl
 739 Acad Sci U S A 2009;106:10620-5
- Fraumeni JF, Jr., Glass AG. Rarity of Ewing's sarcoma among U.S. Negro children.
 Lancet 1970;1:366-7
- Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP.
 Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer 2009;115:3526-36
- Randall RL, Lessnick SL, Jones KB, Gouw LG, Cummings JE, Cannon-Albright L, *et al.* Is There a Predisposition Gene for Ewing's Sarcoma? J Oncol 2010;2010:397632
- Machiela MJ, Grünewald TGP, Surdez D, Reynaud S, Mirabeau O, Karlins E, *et al.*Genome-wide association study identifies multiple new loci associated with Ewing
 sarcoma susceptibility. Nat Commun **2018**;9:3184
- 751 22. Grünewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM,
 752 *et al.* Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2
 753 via a GGAA microsatellite. Nat Genet **2015**;47:1073-8
- Aynaud MM, Mirabeau O, Gruel N, Grossetete S, Boeva V, Durand S, *et al.*Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at
 Single-Cell Resolution. Cell Rep 2020;30:1767-79.e6
- Barberi T, Willis LM, Socci ND, Studer L. Derivation of multipotent mesenchymal
 precursors from human embryonic stem cells. PLoS Med 2005;2:e161
- Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitinger S, Kloss F, *et al.*Reduced oxygen tension attenuates differentiation capacity of human mesenchymal
 stem cells and prolongs their lifespan. Aging Cell **2007**;6:745-57
- Renouf B, Piganeau M, Ghezraoui H, Jasin M, Brunet E. Creating Cancer
 Translocations in Human Cells Using Cas9 DSBs and nCas9 Paired Nicks. Methods in
 enzymology 2014;546:251-71
- 765 27. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, *et al.*766 Punctuated evolution of prostate cancer genomes. Cell **2013**;153:666-77
- Anderson ND, de Borja R, Young MD, Fuligni F, Rosic A, Roberts ND, *et al.*Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors.
 Science 2018;361
- Boeva V, Surdez D, Guillon N, Tirode F, Fejes AP, Delattre O, *et al.* De novo motif
 identification improves the accuracy of predicting transcription factor binding sites in
 ChIP-Seq data analysis. Nucleic Acids Res 2010;38:e126
- Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, *et al.*Functional, chemical genomic, and super-enhancer screening identify sensitivity to
 cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget 2015;6:30178-93
- Baldauf MC, Orth MF, Dallmayer M, Marchetto A, Gerke JS, Rubio RA, *et al.* Robust
 diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancerdriven EWSR1-ETS targets. Oncotarget **2018**;9:1587-601
- Marchetto A, Ohmura S, Orth MF, Knott MML, Colombo MV, Arrigoni C, *et al.*Oncogenic hijacking of a developmental transcription factor evokes vulnerability
 toward oxidative stress in Ewing sarcoma. Nat Commun 2020;11:2423

- Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, *et al.* Chemically
 modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.
 Nature biotechnology 2015;33:985-9
- Bilke S, Schwentner R, Yang F, Kauer M, Jug G, Walker RL, *et al.* Oncogenic ETS
 fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome
 research 2013;23:1797-809
- Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, *et al.* DNA
 microarrays reveal relationship of Ewing family tumors to both endothelial and fetal
 neural crest-derived cells and define novel targets. Cancer Res 2004;64:8213-21
- 791 36. Tanaka M, Yamazaki Y, Kanno Y, Igarashi K, Aisaki K, Kanno J, *et al.* Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors.
 793 The Journal of clinical investigation **2014**;124:3061-74
- 37. Surdez D, Zaidi S, Grossetête S, Laud-Duval K, Ferre AS, Mous L, *et al.* STAG2
 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and
 EWSR1-FLI1 activity in Ewing sarcoma. Cancer Cell 2021
- Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, *et al.* Systems biology
 of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and
 apoptosis. Nucleic Acids Res 2013;41:8853-71
- 800 39. Campbell PJ, Getz G, Korbel JO. Pan-cancer analysis of whole genomes. Nature
 801 2020;578:82-93
- 40. Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, *et al.* The evolutionary history of 2,658 cancers. Nature 2020;578:122-8
- 41. Lee JJ, Park S, Park H, Kim S, Lee J, Lee J, *et al.* Tracing Oncogene Rearrangements
 in the Mutational History of Lung Adenocarcinoma. Cell 2019;177:1842-57.e21
- Rivera-Mulia JC, Buckley Q, Sasaki T, Zimmerman J, Didier RA, Nazor K, *et al.*Dynamic changes in replication timing and gene expression during lineage
 specification of human pluripotent stem cells. Genome research 2015;25:1091-103
- 43. Jahromi MS, Jones KB, Schiffman JD. Copy Number Alterations and Methylation in
 Ewing's Sarcoma. Sarcoma 2011;2011:362173
- 44. Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S, *et al.* Genetic
 imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes
 Chromosomes Cancer 2001;32:164-71
- Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, *et al.*Clock-like mutational processes in human somatic cells. Nat Genet 2015;47:1402-7
- 46. Watson S, Perrin V, Guillemot D, Reynaud S, Coindre JM, Karanian M, *et al.*Transcriptomic definition of molecular subgroups of small round cell sarcomas. The
 Journal of pathology 2018;245:29-40
- 819

- 821 **FIGURE LEGENDS**
- 822

Figure 1. Generation of EWIma1 cells derived from MSC^{Pat} cells, recapitulating 823 824 molecular and epigenetic features of EwS.

A- CRISPR/Cas9 based strategy to obtain EWSR1-FLI1 translocated clones from MSCs with 825 or without inducing *STAG2*, *TP53* and *CDKN2A* additional mutations. EF: gRNA^{EWS} and gRNA^{FLII}. EF+SPC: gRNA^{EWS}, gRNA^{FLII}, gRNA^{TP53}, gRNA^{CDKN2A} and gRNA^{STAG2}. **B**- Cumulative cell counts over time in EWIma1 cells transfected with siRNA targeting 826 827

- 828
- 829 EWSR1-FLI1 (si-EF1) compared to wild type (WT) and siRNA control (si-CTL). Top, 830 western blot against EWSR1-FLI1, shown at 4 days post transfection. Results represent the 831 mean \pm SD from three independent experiments. * p<0.05.
- 832 C- Representative image of spectral karyotype (SKY multi-colored fluorescent FISH analysis) obtained from EWIma1 cells with a chromoplectic like pattern (reciprocal 833 834 translocations t(11;22)(q24;q12), t(13;17), t(17;9) and derivative chromosome 11 (der11) of 835 t(11;13)). N= 22. See also Supplementary Table 1.
- 836 **D-** Schematic circos plot of the main rearrangements seen in EWIma1 cells (dot lines: 837 rearrangements not found in all cells).
- 838 E- Integrative Genomics Viewer representation for FLI1 and H3K27ac ChIP-seq profiles at
- 839 DKK1 locus showing the disappearance of super-enhancer in EWIma1, and A673 cells
- compared to MSC^{Pat}. Super-enhancers are framed in red. 840
- F- Integrative Genomics Viewer representation for FLI1 and H3K27ac ChIP-seq profiles at 841 842 *PRKCB. CCND1* and *NKX2-2* loci showing the appearance of super-enhancers in EWIma1. and A673 cells compared to MSC^{Pat}. Super-enhancers are framed in red. 843
- G- Top two motifs predicted by ChIPMunk corresponding to known motifs in Jaspar database 844 identified in EWIma1 and MSC^{Pat} FLI1 ChIP-seq data. 845
- H- Left: Heatmap representation of FLI1 ChIP-seq peaks ranked by intensity at GGAA 846 microsatellite (GGAAm) or ETS sites in EWIma1 only or MSC^{Pat} common sites. Right: 847 848 Heatmap representation of H3K27ac ChIP-seq peaks sorted by ROSE SE rank in EWIma1 849 and MSC^{Pat} specific and common sites. A673 data are shown as control. Read density is 850 displayed within a 5kb (H3K27ac or FLI1) window around peak center and color scale 851 intensities are shown in normalized coverage (scale is shown on the right of each panel).
- 852

853 Figure 2. Molecular characterization of a collection of EWIma cells derived from MSC^{Pat} cells. 854

- **A** Representative images of agar colony formation assays using combinations of gRNA^{*EWS*} (*E*), gRNA^{*FLII*} (*F*), gRNA^{*TP53*} (*P*), gRNA^{*CDKN2A*} (*C*), and gRNA^{*STAG2*} (*S*). 855 856
- 857 **B**- Colony size quantification mean +/- SD, p value (* p= 0.0186; ** p=0.0029; 858 ****p<0.0001); n>600 colonies per condition.
- C- Nested PCR to detect the translocated chromosome derivative 22 (der22) on serial 859 dilutions from a DNA pool of MSC^{Pat} cells transfected with EF+SPC gRNAs (from 50 to 1.6 860 ng in triplicates). Translocation frequency (f) is calculated as described in (26) using the 861 assumption that a human diploid cell contains ~6 pg of DNA. 862
- D- Western blot against EWSR1-FLI1 in a panel of EWIma clones compared to positive 863 (A673) and negative (MSC^{Pat}) controls. Vinculin is used as loading control. 864
- E- Representative images of cellular morphology for the negative EWSR1-FLI1 translocated 865 MSC-SPC-#5 clone (with typical MSC morphology), for a positive EWSR1-FLI1 866 867 translocated EWIma11 (intermediate EwS morphology) and EWIma7 (classical EwS 868 morphology) clones. Scale bar: 800 µm.

- 869 F- Telomerase Repeat Amplification Protocol (TRAP) assay showing telomerase activity in
- the different EWIma clones compared to A673 Ewing cells (A), MSC-SPC-#5 (CTL) and
- 871 MSC^{Pat} cells.
- 872 **G-** Karyotype analysis of EWIma7.
- 873 **H-** Karyotype analysis of EWIma5.
- 874 I- Karyotype analysis of EWIma14.
- 875
- 876
- 877

878 Figure 3. EWSR1-FLI1 transcriptional signature is predominant in the *de novo* models.

A- Histogram for weight percentage of top 10 dimensions of principal component analysis(PCA).

- B- PCA representation for parental and hMPC or MSC^{Pat} derived models (including *in vitro*,
 in vivo and EWSR1-FLI1 silenced EWIma1 models) compared to a collection of EwS cell
- 883 lines. Left: PC1 vs PC2 and right: PC1 vs PC3.

884 **C**- Unsupervised Hierarchical clustering and heatmap based on top 1% inter-quartile range 885 gene expression values. EWIma^{low} models (EWIma12, 11, 31 and 30) are framed in red. 886 EWIma orthotopic tumors (EWIma1, 5 and 7) are framed in brown. EwS cell lines are framed 887 in black. R_n : biological replicates numbering.

- **D** GSEA enrichment plots from top signatures upon MSC^{Pat} versus EWIma models comparison. Top MSC^{Pat} correlated signatures included commonly down-regulated genes in mesenchymal progenitors upon EWSR1-FLI1 and EWSR1-ERG expression (Myagawa targets of EWSR1-ETS fusions DN) and the hallmark epithelial to mesenchymal transition gene sets. Top EWIma correlated signatures included the cell cycle independent EWSR1-FLI1 activation signature (IC_EWS from (23)) and up-regulated genes in embryonic
- fibroblasts upon serum stimulation and E2F3 knockdown (KONG_E2F3_TARGETS). In this analysis, EWIma^{low} models were excluded.
- 896

897 Figure 4. *In vivo* tumors obtained from engineered EWIma7 cells

A- Western blot against EWSR1-FLI1 in EWIma 5, 7 and 1 tumor cells and parental EWIma1
cells.

900 **B**- Histology of EWIma7 tumors (representative images). Top panel row: left, H&E staining 901 in tumors at primary orthotopic implantation site (scale bar 200 μ m) and anti-CD99 IHC 902 staining at lung metastatic sites (scale bar, middle panel: 1 mm, right panel: 50 μ m). Middle 903 row left panel: magnification of H&E in the primary orthotopic tumor displaying a classical 904 small round tumor cell morphology (scale bar: 50 μ m). Additional IHC stainings against 905 CD99, FLI1, STAG2, Ki67 and cleaved CASP3 (clCASP3) in primary orthotopic tumors are 906 shown in middle and bottom panel rows (scale bar: 50 μ m).

907

908 Table 1: Representative panel of genetic and morphologic features of EWIma model.

909 Sequences of STAG2, TP53 and CDKN2A mutations and cellular morphology (+ classical

- 910 EwS morphology, +/- intermediate EwS morphology or MSC morphology) are indicated.
 911 Genomic sequences of der11 and der22 at breakpoints are indicated. MSC-SPC-#5 clone does
- 911 Obtained sequences of del 11 and del 22 at breakpoints are indicated. MSC-SPC-#5 clone does 912 not contain the EWSR1-FLI1 translocation and is used as negative control. EWINGness score
- for each EWIma model is displayed in the last column (see also **Supplementary Table 2**).
- 914 "No seq" means that no sequence was PCR amplified for these clones probably due to large
- 915 DNA deletions or presence of translocation implicated the gene.
- 916

Figure 1





Figure 2







Figure 4



В



HES-LEG	CD99-LUNG	CD99-LUNG	The state
	and the second		(D)
and the second se			Real Trans
HES-LEG	CD99-LEG	FLI1-LEG	
			1944 - C
		Section and	
STAG2-LEG	Ki67-LEG	clCASP3-LEG	
			a partie
a third and the first			Read
the first			and the second second
- Total Alex	the state of the		Sale Mar

Table 1

Name	STAG2	TP53	CDKN2A	Mophology	Der11	Der22	Score*
EWIma2	c.661_662insT	c.831delG	c.512_513insG / c.512_514insTT	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	70,0
EWIma3	c.661_662insT	no seq	c.512_513insG / c.512_514insTT	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	66,6
EWIma13	c.661_662insT	c.831delG	c.512_513insG / c.512_514insTT	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	66,5
EWIma10	c.661_662insT	c.831delG / c.817_838del	c.513delT / c.512_513del	+	Del204 - Del24	Del70 - Del15	66,2
EWIma14	c.661_662insT	c.811_830del	c.512_513insT	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	65,4
EWIma4	c.661_662insT	c.831delG	c.512_513insG	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	65,4
EWIma6	c.661_662insT	c.831delG / c.832_833insCC	c.512delG / c.512_513insT	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	64,5
EWIma7	c.661_662insT	c.831_832insG / c.831_837del	c.512_513insT	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	61,4
EWIma9	c.661_662insT	c.831delG	c.512_513insT / c.511_512del	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	60,8
EWIma5	no seq	c.811_830del	c.512_513insT	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	60,4
EWIma8	c.661_662insT	c.831_832insG / c.831_837del	c.512_513insT	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	60,1
EWIma1	c.661_662insT	c.831delG	c.511_519del	+	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	58,3
EWIma11	c.661_662insT	c.832_833insC / c.831delG + c.834C>T	c.512_515del / c.512_513insT	+/-	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	40,9
EWIma12	c.661_662insT	c.832_833insC / c.831delG + c.834C>T	c.512_513insG	+/-	TCCAGCTA-CTTCACAC	TTTCCTAT-TAAACATCT	33,5
MSC-SPC#5	c.660_662del	c.831_836del / c.815_836del	c.509_516del / c.512_513insT	_	-	-	0,0